I. MODIFIED AGREEMENTS

Biotech Co.*
(Country; Symbol)

Pharma Co.
(Country)

Change from original agreement

Terms/Details (Date)


BioXell SpA*
(Italy)

F. Hoffmann-La Roche Ltd. (Switzerland)

BioXell gained additional rights to BXL 628 to include all nontopical and nonderma-tological applications

BioXell already held rights in several indications; terms were not disclosed (6/28)

Chemical Diversity Labs Inc.*

Gedeon Richter Ltd. (Hungary)

Extended agreement under which Chemical Diversity provides discovery chemistry libraries and medicinal chemistry services

The deal was extended through 2006; terms were not disclosed (8/9)

Crucell NV (the Netherlands; CRXL)

GlaxoSmithKline plc (UK)

GSK renewed its PER.C6 license for R&D of viral- vectored products

Crucell gets undisclosed up-front and annual payments; GSK has an option to get a commercial license (7/6)

Europroteome
AG*
(Germany)

Abbott Laboratories

They extended deal for the discovery and development of breast cancer diagnostics

The February 2004 deal was extended after reaching an undisclosed project milestone (7/15)

Genedata AG* (Switzerland)

Altana AG
(Germany)

Expanded deal under which Genedata will provide enterprise-wide computing infrastructure

The original license five years ago covered Genedata's scientific computing platform; Altana will use the technology in target discovery and lead identification (6/29)

Immunomedics
Inc.
(IMMU)

Schering AG (Germany)

Settled issues related to in vitro products covered under Immunomedics' CEA patents

Schering unit CIS Bio International will pay Immunomedics an undisclosed sum for past sales of the products (7/7)

Interleukin
Genetics Inc.
(OTC BB:ILGN)

Access Business Group (subsidiary of Alticor Inc.)

Expanded deal to include development of a test to identify genetic variations that affect weight gain

IGI can get $1.9M over a 12-month proof- of-concept period; IGI also will help in developing nutritional products to help manage weight (7/1)

Karo Bio AB (Sweden; SSE:KARO)

Wyeth

Extended for one year deal to discover drugs targeting the liver X receptor

The three-year deal was extended to Aug. 31, 2005, and is focused primarily on atherosclerosis; terms were not disclosed (6/18)

Medivir AB
(Sweden; SSE:MVIR)

Novartis AG (Switzerland)

They resolved issues related to partly overlapping patents in the U.S. on Medivir's ME-609 product

Medivir gets exclusive rights to topical combination products containing the antiviral acyclovir; Novartis gets a non-exclusive license to certain antiviral combination products, while Medivir retains the exclusive rights to its formulation patent relating to combinations containing penciclovir (8/13)

Neuro3d SA*
(France)

Johnson & Johnson Pharmaceutical Research & Development

Extended collaboration after J&J identified a compound for further characterization from Neuro3d's libraries

Details were not disclosed (7/21)

Prana Biotechnology Ltd. (Australia; PRAN)

P.N. Gerolymatos SA (Greece) to the Alzheimer's disease

They, along with Massachusetts General Hospital, resolved all pending litigation related and will pay Prana a percentage of income; drug lioquinol

Prana will hold rights in the U.S. and Japan, and pay royalties on those sales; Gerolymatos holds rights in Europe and elsewhere, PRAN) Prana will allot 1.35M shares that will beheld in escrow for 12 months (8/9)

Sepracor Inc.
(SEPR)

Paul Royalty Fund II LP

Paul Royalty acquired royalty rights to Sepracor's Estorra from Aventis SA

Paul Royalty will pay Aventis up to $115M in fixed and milestone payments following product launch (8/9)

Symyx Technologies Inc. (SMMX)

Dow Chemical Co.

Extended collaboration to discover catalysts to produce polyolefins, which are polymers used in various products

The 1999 deal was extended through 2004, giving them time to define future business arrangements (6/30)

II. TERMINATED AGREEMENTS

Alliance Pharmaceutical Inc. (OTC BB:ALLP)

Nycomed Group (Denmark)

Terminated deal signed in April under which Nycomed would commercialize Oxygent in Europe

The move was made after an opinion by European regulators suggesting more clinical study would be needed on the blood substitute than originally anticipated (7/6)

AVI BioPharma Inc. (AVII)

Medtronic Inc.

Ended deal on the delivery of AVI's antisense therapy Resten-NG, via devices, in cardiovascular diseases

The deal was signed in 2001 and modified in 2003; AVI regains full exclusive rights to Resten-NG in all cardiovascular applications, including device delivery (6/30)

Elite Pharmaceuticals Inc. (AMEX:ELI)

Purdue Pharma LP

Purdue allowed to lapse its exclusive option to apply abuse-resistant technology to oxycodone

Elite intends to recommence negotiations on licenses to the technology with other companies (8/4)

Generex Biotechnology
Corp.
(Canada; GNBT)

Eli Lilly and Co.

Ended deal to develop and commercialize buccal delivery of insulin

Generex regains full rights to the technology, which includes its Oralin product; Lilly will continue supplying insulin (6/23)

Geron
Corp.
(GERN)

Kyowa Hakko Kogyo Co. Ltd. (Japan)

Kyowa Hakko returned Asian rights for Geron's telomerase inhibitors

They said Kyowa Hakko is refocusing its oncology development programs (6/30)

Illumina
Inc.
(ILMN)

Applera Corp. and its Applied Biosystems Group

Companies settled litigation related to a 1999 development agreement; the settlement ended the agreement

They agreed to royalty-free cross-licenses and an $8.5M payment from Illumina to Applera, part of $10M it received earlier in the deal in R&D funding (8/19)

Inex
Pharmaceuticals
Corp.
(Canada;
TSE:IEX)

GlaxoSmithKline plc (UK)

GSK is terminating their deal to develop liposomal topotecan (INX-0076; Hycamtin) effective Sept. 1, 2004

The deal to apply Inex liposomal technology to the GSK compound began in 2001; GSK ran into manufacturing difficulties (8/4)

Novavax Inc. (NVAX)

King Pharmacueticals Inc.

Novavax regained full rights to Estrasorb, as well as all rights to other women's health products Novavax may develop using micellar nanoparticle technology

They ended a co-promotion deal on the product; Novavax will pay King $22M in cash and issue 3.78M shares, giving King about 10.4% of Novavax; Novavax will reacquire convertible notes held by King and acquire part of King's women's health sales force; King will pay Novavax $8M to support marketing efforts (7/19)


Notes:

# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange.

No Comments